Bavarian Nordic (OTCMKTS:BVNRY) Sees Unusually-High Trading Volume – Should You Buy?

Shares of Bavarian Nordic (OTCMKTS:BVNRY) saw unusually-strong trading volume on Monday . Approximately 2,518 shares were traded during trading, an increase of 36% from the previous session’s volume of 1,854 shares.The stock last traded at $10.43 and had previously closed at $10.44.

Bavarian Nordic Price Performance

The stock has a market cap of $2.50 billion, a PE ratio of 6.79 and a beta of 1.34. The business has a fifty day moving average of $9.90 and a 200-day moving average of $11.07.

Bavarian Nordic (OTCMKTS:BVNRY) last announced its quarterly earnings data on Friday, November 14th. The company reported $0.72 earnings per share for the quarter. Bavarian Nordic had a net margin of 35.96% and a return on equity of 20.47%. The firm had revenue of $281.11 million for the quarter. As a group, equities research analysts predict that Bavarian Nordic will post 0.67 EPS for the current year.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.